Suraxavir Marboxil
Phase 3Small molecule
Suraxavir Marboxil is one of 83 small molecule programs targeting Influenza. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Platelet Rich Plasma
ZZagazig University
Phase 3
Suraxavir Marboxil
JJiangxi Kvvit Pharmaceutical Co., Ltd.
Phase 3
Endothelin Receptor Antagonist
RRadboud University Medical Center
Phase 3
Cetaphil
GGalderma R&D
Phase 3
Levocept
SSebela Women's Health Inc.
Phase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Influenza1 trial
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
Recruiting·—·Phase 3·NCT07236814·384 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Suraxavir Marboxil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details